Article

Increasing HIV Pre-exposure Prophylaxis in the Homeless Requires Effort

Only 15% of those at risk are currently using PrEP.

Pre-exposure prophylaxis (PrEP) is highly effective in preventing HIV-1 acquisition. PrEP is currently underutilized among at-risk populations, such as homeless veterans.

In 2014, the CDC released recommendations for universal screening of all patients for HIV risk factors. It also recommended initiating oral PrEP (tenofovir-disoproxil fumarate/emtricitabine and tenofovir alafenamide/emtricitabine [TDF/FTC]) for eligible patients. The United States Preventive Task Force reinforced this policy in June 2019 with a grade A recommendation that clinicians offer PrEP to those who have a high risk of obtaining HIV.

Only 15% of those at risk are currently using PrEP. The annual number of new HIV infections in the United States has been fairly stable since 2010. This trend over the last few years can be directly related to inadequate prevention outreach for high-risk groups.

The Veterans Health Administration is the largest provider of HIV care in the United States. It is also the largest single provider of health care services to the homeless population. People who are homeless have worse health outcomes and higher mortality rates than the general population. Those who are homeless have 27-fold higher independent odds of death compared to those who have housing.1

The VA of Greater Los Angeles Healthcare System served approximately 3600 homeless veterans at 3 Homeless Patient Aligned Care Team (HPACT) clinics from September 2018 to August 2019. Researchers from the VA and the David Geffen School of Medicine at UCLA assigned a group of 23 clinic staff and trainees to determine baseline awareness, knowledge, and attitudes about HIV risk behavior and prescribing PrEP. Results of the study published in the Journal of Primary Care & Community Health showed low utilization of PrEP, with only 8% of eligible veterans currently prescribed PrEP. 2

Only 22% of providers participating in the study stated they were comfortable talking about PrEP with patients. Some barriers included inadequate knowledge to answer patient questions or total lack of awareness of PrEP. After 3 months of educational training developed by the quality improvement team, the percentage of staff that was able to accurately identify patients who qualify for PrEP increased from 30% to 55%. The number of PCPs who felt comfortable talking about PrEP with patients increased from 22% to 40%.2

The VA National Formulary restricts specialty medications including TDF/FTC to specialist prescribers. Interested providers completed a 1-hour VA specific PrEP training, and submitted the training documentation to the pharmacy and therapeutics committee. This process allowed PCPs and clinical pharmacists to prescribe PrEP in the VA health care system. 2

PrEP is an extremely important HIV prevention tool and is currently underutilized in high-risk populations especially those suffering with homelessness. Health care systems should focus on reducing patient barriers to PrEP access including specialist referrals, cost, patient education, and inconvenience of additional appointments. Expanding the capacity of primary care to provide PrEP and other HIV prevention strategies is crucial to end the HIV epidemic, especially individuals suffering with homelessness.

Aaron Wang is a 2020 PharmD candidate at the University of Connecticut in Storrs.

REFERENCES

  • Spinelli MA, Hessol NA, Schwarcz S, et al. Homelessness at diagnosis is associated with death among people with HIV in a population-based study of a US city. AIDS. 2019;33:1789-1794.
  • Gregg E, Linn C, Nace E, Gelberg L, Cowan B, Fulcher JA. Implementation of HIV Preexposure Prophylaxis in a Homeless Primary Care Setting at the Veterans Affairs. J Prim Care Community Health. 2020;11:2150132720908370.

Related Videos
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Hurricane Helene, Baxter plant, IV fluids shortage, health systems impact, injectable medicines, compounding solutions, patient care errors, clinical resources, operational consideration, fluid conservation, sterile water, temperature excursions, training considerations, patient safety, feedback request
Image Credit: © peopleimages.com - stock.adobe.com
Pharmacists, Education, Advocacy, Opioid Awareness Month | Image Credit: Jacob Lund - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards